In addition, they evaluated the diagnostic performance of a biomarker panel based on AFP levels, serum expression of miR-122 and circulating cell-free DNA mutations in the promoter of the Telomerase Reverse Transcriptase (TERT) gene, for distinguishing the different groups of HBV-related liver disease patients. This evidence concerns the gene AFP and liver disorder.